A potential shakeup in the Prescription Drug User Fee Act renewal process is taking shape after Democrats’ midterm election wins, according to STAT+. The FDA’s drug-review funding model depends on reauthorizing the user-fee agreement before the current law expires on Sept. 30, with lapse risk tied to the agency’s ability to approve medicines. Sen. Bernie Sanders is highlighted as a key figure likely to shape negotiations, given his prominent role in senior Senate Democrats and his long-standing opposition to the user-fee structure’s core premise.